Summary
0M26 Chart
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.39 per share a year ago.
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
XOMA Royalty Corporation preferred stocks offer diversification beyond mREITs and banks, but both XOMAO and XOMAP are now rated Sell. Recent high-cost financing and low tangible common equity raise risk concerns; both preferreds trade above par with limited call risk but high downside if called. XOMAP likely faces a call first, but both issues suffer from illiquidity, negative cash flow, and asset coverage concerns relative to similar-yielding regional bank preferreds.
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
XOMA Corporation (0M26) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has XOMA Corporation ever had a stock split?
XOMA Corporation Profile
| Biotechnology Industry | Healthcare Sector | Owen P. Hughes Jr. CEO | LSE Exchange | US98419J2069 ISIN |
| US Country | 13 Employees | - Last Dividend | 18 Aug 2010 Last Split | 16 Dec 2020 IPO Date |
Overview
XOMA Corporation is a unique entity in the biotech space, categorizing itself as a biotech royalty aggregator. Based in Emeryville, California, and operational since 1981, the company has carved a niche for itself by focusing on the aggregation of economic rights related to milestone and royalty payments. These payments are expected from partnered therapeutic candidates, which are either in the commercial stage or the pre-commercial development stages across the United States and the Asia Pacific region. By centering its operations on acquiring these revenue streams from both commercial and late-stage clinical assets, XOMA leverages the potential financial returns without directly involving itself in the development, manufacturing, or marketing of these therapeutic solutions.
Products and Services
- Economic Rights Acquisition:
XOMA’s core business model involves acquiring economic rights to future potential milestone and royalty payments across a broad spectrum of therapeutic candidates. This innovative approach allows XOMA to benefit from the success of a wide range of therapies without bearing the significant costs and risks associated with their development.
- Partnered Commercial and Pre-Commercial Therapeutic Candidates:
The company’s portfolio is diverse, encompassing a variety of therapeutic candidates that are either in the commercial stage or moving towards it. These candidates are licensed to partners who manage their development, allowing XOMA to collect milestone payments and royalties upon their commercial success.
- Focus on Early to Mid-Stage Clinical Assets:
In its selective investment strategy, XOMA emphasizes the licensing of early to mid-stage clinical assets, especially those in Phase 1 and 2. The company seeks assets with high commercial sales potential, enabling it to secure a financial stake in their success at an earlier phase of development.
- Acquisition of Milestone and Royalty Revenue Streams:
Further solidifying its business model, XOMA also focuses on acquiring existing milestone and royalty revenue streams from late-stage clinical or already commercialized assets. This strategy provides a more immediate financial return while maintaining a diversified portfolio.
Contact Information
